[go: up one dir, main page]

FI944534L - Rapamysiinikoostumuksia oraalisesti annettaviksi - Google Patents

Rapamysiinikoostumuksia oraalisesti annettaviksi Download PDF

Info

Publication number
FI944534L
FI944534L FI944534A FI944534A FI944534L FI 944534 L FI944534 L FI 944534L FI 944534 A FI944534 A FI 944534A FI 944534 A FI944534 A FI 944534A FI 944534 L FI944534 L FI 944534L
Authority
FI
Finland
Prior art keywords
oral administration
rapamycin compositions
rapamycin
compositions
oral
Prior art date
Application number
FI944534A
Other languages
English (en)
Swedish (sv)
Other versions
FI944534A0 (fi
Inventor
Robert Paul Waranis
Thomas Waymond Leonard
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of FI944534A0 publication Critical patent/FI944534A0/fi
Publication of FI944534L publication Critical patent/FI944534L/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
FI944534A 1993-09-30 1994-09-29 Rapamysiinikoostumuksia oraalisesti annettaviksi FI944534L (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12952493A 1993-09-30 1993-09-30

Publications (2)

Publication Number Publication Date
FI944534A0 FI944534A0 (fi) 1994-09-29
FI944534L true FI944534L (fi) 1995-03-31

Family

ID=22440418

Family Applications (1)

Application Number Title Priority Date Filing Date
FI944534A FI944534L (fi) 1993-09-30 1994-09-29 Rapamysiinikoostumuksia oraalisesti annettaviksi

Country Status (10)

Country Link
EP (1) EP0650730A1 (fi)
JP (1) JPH07149656A (fi)
KR (1) KR950007857A (fi)
CN (1) CN1109746A (fi)
AU (1) AU7420494A (fi)
BR (1) BR9403947A (fi)
CA (1) CA2133174A1 (fi)
FI (1) FI944534L (fi)
HU (1) HUT71131A (fi)
IL (1) IL111003A0 (fi)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
AU688782B2 (en) * 1993-09-30 1998-03-19 Wyeth Rapamycin formulations for oral administration
US5880101A (en) * 1994-06-28 1999-03-09 Dr. Zerle Gmbh Clinical uses of polyene macrolides
DK0789580T3 (da) 1994-11-03 2002-09-09 Novartis Ag Nye præparatformer for cyclosporin til oral administration med simpel sammensætning og høj biotilgængelighed, og fremgangsmåder til deres fremstilling
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
DE60319118T2 (de) 2002-07-30 2009-02-05 Wyeth Parenterale formulierungen mit einem rapamycin hydroxyester
CA2498191C (en) 2002-09-18 2012-04-10 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
US20050032674A1 (en) * 2003-07-03 2005-02-10 Kelly Ciaran P. SAIF, an anti-inflammatory factor, and methods of use thereof
CN104147005B (zh) 2005-02-09 2018-07-03 参天制药株式会社 用于治疗疾病或病症的液体制剂
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
CA2599758A1 (en) * 2005-03-08 2006-09-14 Lifecycle Pharma A/S Pharmaceutical compositions comprising sirolimus and/or an analogue thereof
DE102008059201A1 (de) 2008-11-27 2010-06-02 GÖPFERICH, Achim, Prof. Dr. In situ präzipitierende Arzneistofflösungen
KR101267813B1 (ko) 2009-12-30 2013-06-04 주식회사 삼양바이오팜 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물
WO2012092421A2 (en) * 2010-12-30 2012-07-05 Surmodics, Inc. Composition for intravascular delivery of therapeutic composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019763A1 (en) * 1992-03-30 1993-10-14 American Home Products Corporation Rapamycin formulation for iv injection

Also Published As

Publication number Publication date
KR950007857A (ko) 1995-04-15
CA2133174A1 (en) 1995-03-31
HU9402785D0 (en) 1994-12-28
IL111003A0 (en) 1994-11-28
HUT71131A (en) 1995-11-28
CN1109746A (zh) 1995-10-11
AU7420494A (en) 1995-04-13
JPH07149656A (ja) 1995-06-13
BR9403947A (pt) 1995-06-13
FI944534A0 (fi) 1994-09-29
EP0650730A1 (en) 1995-05-03

Similar Documents

Publication Publication Date Title
DE10199046I2 (de) Rapamycin-Zubereitungen zur oralen Verabreichung
BR9307801A (pt) Composições orais
IS4706A (is) Lyfjasamsetningar
FI20071025L (fi) Farmaseuttisia koostumuksia
IL111007A0 (en) Composition containing rapamycin for oral administration
CY2005007I1 (el) Φαρμακευτικες συνθεσεις που περιεχουν δαριφενακινη
FI955144L (fi) Päällystetyt farmaseuttiset koostumukset
NZ304982A (en) Pyridinyloxy- or pyridinylamino-acetamide derivatives; pharmaceutical compositions
NO962606L (no) Farmasöytisk sammensetning
FI944832A0 (fi) Farmaseuttinen koostumus
ID18352A (id) Komposisi-komposisi farmasi
FI944534L (fi) Rapamysiinikoostumuksia oraalisesti annettaviksi
FI944535L (fi) Rapamysiinikoostumuksia oraalisesti annettaviksi
NO974440L (no) Azatioprinsammensetninger for tykktarmsadministrering
ITMI932540A0 (it) Composizione farmaceutica
EE9900206A (et) N-sulfonüülindoliiniderivaate sisaldavad farmatseutilised kompositsioonid
LV11727A (lv) Farmaceitiska kompozicija
NO996044L (no) Rapamycinformuleringer for oral administrasjon
FI943705L (fi) Farmaseuttiset koostumukset
PT941100E (pt) Composicoes farmaceuticas
ITMI942166A0 (it) Composizioni farmaceutiche miorilassanti
BR9606974A (pt) Composições orais
FI973280L (fi) Farmaseuttinen koostumus
LV10579A (lv) Farmaceitiska kompozicija
FI962979L (fi) Hirudiinia sisältävät farmaseuttiset koostumukset